Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Darolutamide Plus ADT Boosts OS in Metastatic Castration-Sensitive Prostate Cancer

February 18th 2022, 12:51am

Genitourinary Cancers Symposium (ASCO GU)

The addition of darolutamide to androgen deprivation therapy and docetaxel generated better overall survival vs placebo with ADT and docetaxel in patients with metastatic castration-sensitive prostate cancer.

Frontline Niraparib Plus Abiraterone Improves rPFS in HRR Gene–Altered mCRPC

February 17th 2022, 11:49pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of niraparib and abiraterone acetate and prednisone led to a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

Olaparib/Abiraterone Combo Significantly Improves Radiographic PFS in mCRPC

February 17th 2022, 11:40pm

Genitourinary Cancers Symposium (ASCO GU)

Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.

Apalutamide Outperforms Enzalutamide in mCSPC in Real-World Analysis

February 17th 2022, 10:49pm

Genitourinary Cancers Symposium (ASCO GU)

A greater portion of patients with metastatic castration-sensitive prostate cancer achieved an early and deep prostate-specific antigen reduction from baseline of 90% or more when treated with apalutamide compared with enzalutamide.

Efforts to Effectively Target Rare Oncogenes Propel Progress in Lung Cancer

February 10th 2022, 5:00pm

PER® Winter Lung Cancer Conference

With 9 approved markers in non–small cell lung cancer and a plethora of established and emerging therapies that have been designed to target them, the need for molecular testing is more important than ever.

Dr. Bazhenova on Questions With Trastuzumab Deruxtecan in HER2-Mutated Lung Cancer

February 9th 2022, 12:16am

PER® Winter Lung Cancer Conference

Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer.

Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung Cancer

February 8th 2022, 10:52pm

PER® Winter Lung Cancer Conference

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Emerging TKIs Shake Up the Treatment Landscape for EGFR Exon 20 Insertion+ NSCLC

February 8th 2022, 9:38pm

PER® Winter Lung Cancer Conference

Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with non–small cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval.

Neoadjuvant Immunotherapy Proving to Be Effective, Safe Option in Lung Cancer

February 8th 2022, 7:05pm

PER® Winter Lung Cancer Conference

Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.

Dr. Hales on the Role of Multidisciplinary Care in Locally Advanced Lung Cancer

February 7th 2022, 10:50pm

PER® Winter Lung Cancer Conference

Russell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer.

Dr. Levy on Potential Methods to Optimize Molecular Testing in Lung Cancer

February 7th 2022, 10:40pm

PER® Winter Lung Cancer Conference

Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.

ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC

February 7th 2022, 10:34pm

PER® Winter Lung Cancer Conference

Antibody-drug conjugates appear to have the most activity in those with non–small cell lung cancer and HER2 expression.

Repeat Molecular Testing Is Beneficial in EGFR+ NSCLC With Acquired Resistance

February 7th 2022, 9:55pm

PER® Winter Lung Cancer Conference

Repeat histologic evaluation and molecular testing in patients with EGFR-mutant non–small cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions.

Abundance of Immunotherapy Combinations Leaves Treatment Selection Unclear in Advanced NSCLC

February 7th 2022, 9:52pm

PER® Winter Lung Cancer Conference

Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.

Investigators Set Sights Beyond the PACIFIC Regimen in Unresectable Stage III NSCLC

February 7th 2022, 9:35pm

PER® Winter Lung Cancer Conference

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

Immunotherapy Advances Drive Progress in Lung Cancer Treatment

February 5th 2022, 11:17pm

PER® Winter Lung Cancer Conference

In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.

Dr. Basu Roy on Addressing Barriers to Biomarker Testing in Lung Cancer

February 5th 2022, 6:22pm

PER® Winter Lung Cancer Conference

Upal Basu Roy, PhD, MPH, discusses addressing barriers to biomarker testing in lung cancer.

Dr. Hales on Investigational Treatment Strategies to Build Upon the PACIFIC Trial Results in Stage III NSCLC

February 5th 2022, 6:22pm

PER® Winter Lung Cancer Conference

Russell Kenneth Hales, MD, discusses investigational treatment strategies that have the potential to build upon the positive results of the phase 3 PACIFIC trial in stage III non–small cell lung cancer.

Neoadjuvant, Adjuvant Immunotherapies Poised to Revolutionize Outcomes in Resectable NSCLC

February 5th 2022, 5:59pm

PER® Winter Lung Cancer Conference

Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.

Frontline Maintenance Requires Careful Consideration in Advanced Ovarian Cancer

February 1st 2022, 10:47pm

SGO Winter Meeting

Alexander Babatunde Olawaiye, MD, discusses factors that influence optimized frontline maintenance therapy in advanced ovarian cancer.